Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734012 | 0.89 | GNAI3 (0.32) | GNAI3GNAO1GNAI1 | |
| SCHEMBL24908399 | 0.83 | GNAO1 (0.41) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL22733588 | 0.82 | GNAO1 (0.43) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL21214226 | 0.82 | GNAO1 (0.43) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL13265256 | 0.82 | — | — | |
| SCHEMBL15478177 | 0.81 | TSHR (0.35) | — | |
| SCHEMBL6627321 | 0.80 | POLB (0.32) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL9990038 | 0.79 | SIGMAR1 (0.34) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL3388002 | 0.78 | SIGMAR1 (0.31) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL19362479 | 0.78 | ADRB1 (0.31) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | UTI LIMITED PARTNERSHIP (CA) | 2019-03-12 | — | — | US | disclosed |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2017-08-17 | — | — | US | disclosed |
| WO-2008053131-A1 | HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227332-B2 | T-type calcium channel modulator and uses thereof | CACNA1E, CACNA1G, TRPC6 | SIGMAR1 500/4885GNAI3 861/4885GNAO1 529/4885 |
| US-20170233374-A1 | T-TYPE CALCIUM CHANNEL MODULATOR AND USES THEREOF | CACNA1E, CACNA1G, TRPC6 | SIGMAR1 566/4885GNAI3 833/4885GNAO1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.